- Home
- AXGN
AXGN
Axogen Inc.
as 06-30-2025 11:30am EST
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | ALACHUA |
| Market Cap: | 538.3M | IPO Year: | N/A |
| Target Price: | $23.83 | AVG Volume (30 days): | 625.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.09 - $21.00 | Next Earning Date: | 08-07-2025 |
| Revenue: | $194,520,000 | Revenue Growth: | 18.81% |
| Revenue Growth (this year): | 18.08% | Revenue Growth (next year): | 16.15% |
Stock Insider Trading Activity of Axogen Inc. (AXGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| TYNDALL JOSEPH A. | AXGN | Director | Jun 10 '25 | Sell | $10.72 | 26,931 | $288,700.32 | 0 | |
| JOHNSON JOHN | AXGN | Director | Jun 9 '25 | Sell | $10.61 | 4,073 | $43,214.53 | 24,943 | |
| Weiler Kathy Johnson | AXGN | Director | Jun 9 '25 | Sell | $10.61 | 4,073 | $43,214.53 | 6,580 | |
| Wendell Amy McBride | AXGN | Director | Jun 9 '25 | Sell | $10.61 | 4,073 | $43,214.53 | 93,826 | |
| Burke William P. Mr. | AXGN | Director | Jun 9 '25 | Sell | $10.61 | 4,073 | $43,214.53 | 24,484 | |
| NEELS GUIDO J | AXGN | Director | Jun 9 '25 | Sell | $10.61 | 4,073 | $43,214.53 | 86,743 | |
| Levine Alan M | AXGN | Director | Jun 9 '25 | Sell | $10.61 | 4,073 | $43,214.53 | 36,743 | |
| TYNDALL JOSEPH A. | AXGN | Director | May 22 '25 | Sell | $11.20 | 20,062 | $224,694.40 | 0 | |
| TYNDALL JOSEPH A. | AXGN | Director | May 19 '25 | Sell | $11.63 | 2,525 | $29,365.75 | 0 |
Latest Axogen Inc. News
AXGN Breaking Stock News: Dive into AXGN Ticker-Specific Updates for Smart Investing
MT Newswires
19 days ago
Axogen Insider Sold Shares Worth $288,700, According to a Recent SEC Filing
GlobeNewswire
a month ago
Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference
Zacks
a month ago
AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Simply Wall St.
2 months ago
Axogen First Quarter 2025 Earnings: EPS Misses Expectations
Simply Wall St.
2 months ago
Axogen, Inc.'s (NASDAQ:AXGN) Intrinsic Value Is Potentially 87% Above Its Share Price
GuruFocus.com
2 months ago
Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ...
Zacks
2 months ago
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
Associated Press Finance
2 months ago
AxoGen: Q1 Earnings Snapshot
Compare AXGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AXGN Axogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.